Overview of Flukonazol

Property	Description
Active Ingredient	Fluconazole (INN)
Pharmacological Class	Systemic Antifungal Agent, Triazole Derivative
Common Forms	Capsules, Tablets, Oral Suspension, Solution for Infusion
Origin	Synthetic (Chemically Synthesized)
Purpose	To halt the growth and proliferation of fungal infections systemically

What Type of Medicine is Flukonazol (Fluconazole)?

Flukonazol is a synthetic, prescription-only medication classified as a systemic antifungal agent. Its active substance is Fluconazole. Fluconazole belongs to the azole antifungal pharmacological class, specifically characterized as a triazole derivative. This categorization means the drug is designed to address fungal infections that have spread internally throughout the body, acting as a fungistatic agent that primarily inhibits fungal growth. The drug is defined by its selective chemical structure, a nitrogen-containing heterocyclic compound, which contributes to its broad spectrum of activity against various yeasts and fungi.

Composition and Available Forms of Flukonazol

The core composition of this medicine is the single active ingredient, Fluconazole, combined with inert pharmaceutical excipients or vehicles. Flukonazol is available in multiple forms to allow for flexible administration, including solid oral forms such as capsules and tablets, as well as a liquid oral suspension. Crucially, it is also prepared as a solution for infusion, allowing for direct intravenous (IV) administration. Fluconazole is considered well-absorbed after oral dosing, establishing its utility as an orally active agent intended for systemic action. This high bioavailability ensures the medicine can effectively reach internal sites of infection after being taken by mouth, a feature that differentiates it among certain older antifungal classes.

What is the General Purpose of a Systemic Antifungal Agent?

The general therapeutic purpose of Flukonazol is to halt the proliferation of pathogenic fungi responsible for internal infections. The medicine's activity is clinically recognized for its effectiveness across various patient groups, including immunocompromised patients. The drug achieves this by interfering with the fungus's ability to build and maintain its cell membrane. This fungistatic action stops the growth of fungal organisms, such as those from the Candida species, thereby assisting the body in resolving widespread or deep-seated fungal conditions. Its classification as a systemic agent signifies that its function is to provide comprehensive, internal coverage against the underlying fungal cause, serving to contain and prevent the infection from spreading further within the body.

Regulatory References

Therapeutic Uses of Flukonazol

Flukonazol: Main Uses and Therapeutic Benefits

Flukonazol is an antifungal medication utilized to address a variety of fungal and yeast infections throughout the body. The medication's therapeutic benefits stem from its ability to inhibit fungal growth and eradicate the causative agents of infection.

Quick Facts

Treats serious systemic Candida infections, including candidemia and disseminated candidiasis.
Treats infections of the central nervous system, such as cryptococcal meningitis.
Treats mucosal candidiasis affecting the mouth (oropharyngeal candidiasis), throat (esophageal candidiasis), and genital area (vaginal candidiasis).
Used for prophylaxis (prevention) of candidiasis in high-risk patients, such as those undergoing bone marrow transplantation or radiation treatment.

Flukonazol is indicated for the treatment of various fungal afflictions. Its primary uses include addressing systemic Candida infections (invasive candidiasis) and cryptococcal meningitis.

Additionally, this prescription medication is used to treat mucocutaneous candidiasis, which involves infections of the mucous membranes, such as oropharyngeal candidiasis (thrush) and vaginal candidiasis. Flukonazol is also used for the prophylaxis of candidiasis in specific patient populations, such as those with severely compromised immune function due to cytotoxic chemotherapy.

Regulatory References

EMA therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Flukonazol?

Eligibility for Flukonazol is determined by regulatory agencies based on pre-existing conditions and specific population groups.

Populations for Whom Use is Contraindicated

Flukonazol must not be used by patients with a known hypersensitivity to the drug, its excipients, or to other azole antifungal agents. Use is also strictly contraindicated if co-administered with specific medications known to prolong the QT interval, such as pimozide, erythromycin, quinidine, astemizole, and cisapride, as stated in the product label.

Restricted and Conditional Eligibility

Population Group	Regulatory Status
Impaired Renal Function	Use requires caution; dose adjustment is necessary for multiple-dose therapy.
Liver Dysfunction	Requires caution and close monitoring; treatment must be discontinued if signs of severe hepatic injury appear.
Pregnancy	Not recommended unless for severe, life-threatening infections. High-dose and/or prolonged use during the first trimester should not be used due to documented risk of fetal harm.
Age (Under 16)	Single-dose 150 mg treatment is not recommended for children under 16 years of age (per some regulatory labels).
Age (Under 6 months)	Use is permitted, but the dosage must be individually determined by a doctor.

Eligibility is typically established for adults and children (aged 6 months and older) for approved systemic and mucosal fungal infections. Patients with specific hereditary problems, such as fructose intolerance, should not use the oral suspension formulation.

What should I know about interactions with other medicines?

Flukonazol Interactions with other medicines and products

Flukonazol's interaction profile is characterized by its effect on specific liver enzymes, which can alter the concentration of many co-administered medicinal products. The following information reflects officially documented findings from government regulatory sources.

Contraindicated Combinations

Co-administration of Flukonazol is formally contraindicated with certain medications due to the documented risk of serious cardiotoxicity, particularly QTc interval prolongation. These prohibited combinations include Cisapride, Astemizole, Pimozide, Erythromycin, and Quinidine (when metabolized via CYP3A4). Concomitant use with Terfenadine is also prohibited at Flukonazol doses of 400 mg/day or greater.

Pharmacokinetic and Exposure Alterations

Flukonazol is a potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4 and CYP2C19. This inhibition leads to increased plasma concentrations of numerous substrates, including:

Sulfonylureas (e.g., Glipizide, Glyburide), which may result in hypoglycemia.
Oral Contraceptives (Ethinyl Estradiol and Levonorgestrel), for which AUC values are significantly increased.
Warfarin, where co-administration is associated with an increase in prothrombin time ( PT/INR).
Statins (HMG-CoA Reductase Inhibitors), which carry an increased risk of myopathy and rhabdomyolysis when combined with Flukonazol.

Conversely, co-administration with Rifampicin decreases the AUC of Flukonazol by 25%, while Hydrochlorothiazide increases Flukonazol plasma concentrations by 40%.

Mechanism of Action

Molecular Inhibition of Fungal Sterol Synthesis

The function of Fluconazol is defined by its selective interference with the fundamental biology of fungal cells. This mechanism is primarily fungistatic, meaning it stops the growth and proliferation of the fungal organisms. The drug targets the fungal enzyme Lanosterol 14-alpha-demethylase (CYP51) through highly selective competitive inhibition. By blocking CYP51, the drug halts the conversion of lanosterol into ergosterol, the vital sterol required for building the fungal cell membrane.

Destabilization of Fungal Cell Membrane Integrity

This initial molecular action initiates a cascade that results in the structural and functional compromise of the fungal organism. The resulting lack of ergosterol, combined with the toxic buildup of precursor sterols, impairs the fungal cell membrane's integrity and fluidity. This structural damage prevents the fungal cell from maintaining homeostasis and impairs membrane-bound enzyme function, which collectively leads to the cessation of growth and replication of the fungal organisms throughout the body's tissues. The fungistatic action may be constrained by specific fungal countermeasures, including genetic mutations or active drug expulsion via efflux pumps.

Dosage and Administration Information

How to Use Flukonazol (Fluconazole) — Administration Guidelines

Flukonazol (Fluconazole) is administered via the oral route (capsules, tablets, or suspension) or by intravenous (IV) infusion. The pharmacokinetic properties are similar for both routes, and a switch from IV to oral administration is recommended as soon as clinically feasible, without requiring a change in the daily dose.

Dosing and Administration Schedule

Most multi-dose regimens begin with a loading dose on Day 1, which is typically double the subsequent daily dose, to quickly achieve effective plasma concentrations. Following this, the medicine is generally taken once daily. For specific conditions like uncomplicated vaginal candidiasis, the dose is a single oral event of 150 mg.

Oral forms may be taken with or without food as absorption is not affected by meals. The oral suspension must be shaken well before each measured dose. For IV administration, the infusion rate must not exceed 10 mL/ minute.

Population / Condition	Dose Modification (Multiple Doses)	Duration Pattern
Renal Impairment (CrCl ≤ 50 mL/ min)	50% of the recommended daily dose after the initial loading dose	Varies by indication (e.g., ≥ 3 weeks for esophageal candidiasis)
Hemodialysis	100% of the recommended dose is given after each session	Up to 6–12 months for prevention of relapse
Neonates (0–14 days)	mg/ kg dose administered every 72 hours	Prophylaxis may continue for 7 days after neutrophil count rises above 1000 cells/ mm³

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flukonazol

1. Research Evidence for Serious Systemic Fungal Infections

Research has examined Fluconazole's use in systemic infections, such as those caused by Candida in the bloodstream or Cryptococcal Meningitis, which affects the brain and spinal cord. Studies in this area primarily include comparative clinical trials and systematic reviews, which often monitored outcomes related to systemic or functional imbalance and fungal clearance rates over defined short-term periods.

In studies exploring Cryptococcal Meningitis, research has focused on groups of immunocompromised individuals, primarily those with HIV/AIDS. Findings describe patterns related to microbiological clearance in the cerebrospinal fluid (CSF). However, studies indicate that Fluconazole was observed in some studies to be associated with a risk of resistant fungal strains emerging, and the certainty remains low when assessed against different treatment approaches.

2. Studies for Infections of the Mucous Membranes

The evidence for infections affecting the mouth and esophagus (mucosal candidiasis) is derived from Randomized Controlled Trials (RCTs) and long-term observational studies. These trials were primarily used in research exploring how outcomes related to physical discomfort and local infection changed over several weeks of treatment. Findings describe patterns observed in the studies where infection recurrence was observed in some studies during the period of use, but research also highlights that episodes where symptoms become more noticeable may follow the cessation of the study period.

3. Evidence on Prophylaxis (Preventive Use)

Fluconazole was evaluated in clinical trials for its use in prevention, or prophylaxis, in certain high-risk patient groups. Key populations studied include patients undergoing blood and marrow transplant (BMT) and specific groups of critically ill newborn infants (VLBW neonates). Findings describe patterns observed in the studies that monitored the incidence of fungal infections during the period of administration. However, the influence on all-cause mortality has been mixed across different critically ill adult populations, and certainty remains low regarding a broad survival effect across all risk groups.

4. What is Still Uncertain in the Research Landscape

The research on Fluconazole, while extensive, contains known limitations and areas of ongoing study. Data show patterns related to the emergence of resistance in certain species of Candida and Cryptococcus, particularly in populations where the medicine was observed in long periods. Furthermore, long-term effects are not fully established for all indications, and data for certain specific subgroups (e.g., those with comorbidities or specific non-albicans fungal strains) remain insufficient, meaning certainty remains low in these areas.

Frequently Asked Questions (FAQ)

Common questions about Flukonazol (FAQ)

Q: How long does the effect of a single dose of Flukonazol usually last in the body?

A: Official information describes how long the active substance stays in the bloodstream. The terminal plasma elimination half-life of Flukonazol is approximately 30 hours in healthy individuals, though this can range between 20 to 50 hours. This measure indicates the time it takes for half of the drug to be eliminated from the body.

Q: Does Flukonazol interact with common painkillers like ibuprofen?

A: According to official product information, Flukonazol may affect how your body processes certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include common painkillers like ibuprofen. This interaction can lead to an increased concentration of the NSAID in the body, potentially raising the risk of side effects.

Q: Can Flukonazol be taken during pregnancy?

A: Regulatory documents state that use of Flukonazol is generally not recommended during pregnancy and is reserved only for severe or life-threatening infections. Official documents note that high-dose and/or prolonged use during the first trimester is associated with a documented risk of harm to the fetus.

Q: Are generic versions of Flukonazol as effective as the brand-name version?

A: Regulatory standards define a generic version as having the same active ingredient, Fluconazole. According to these standards, generic versions are considered to be therapeutically equivalent to the brand-name product in terms of safety and efficacy.

Q: Is Flukonazol a strong medication?

A: Flukonazol is a systemic antifungal agent that works internally to treat fungal infections. Evidence of its defined effectiveness against serious conditions, such as systemic candidiasis, led the World Health Organization to include it on its List of Essential Medicines.

Q: Can Flukonazol cause a skin rash?

A: Official documents list a general allergic skin rash as an occasional adverse effect. Rare, but serious, skin reactions like Stevens-Johnson syndrome are also documented in the product safety information.

Q: Can Flukonazol be taken by children?

A: Flukonazol is officially indicated for use across a wide age range, including term newborn infants, infants, children, and adolescents up to 17 years old. Eligibility for pediatric use is described in official documents as being dependent on the child's age and the specific fungal infection being addressed.

Q: Can men use Flukonazol?

A: Flukonazol is approved for use in adults, including men, to treat approved systemic and localized fungal conditions. For example, official indications cover certain fungal infections of the genitals in men, such as balanitis.

Q: How quickly does Flukonazol start to work after taking it?

A: For mild and uncomplicated infections treated with a single dose, patient experience suggests that an improvement in symptoms is typically observed within one to three days.

Q: What happens if I miss a dose of Flukonazol?

A: Official product guidance contains specific information on how a patient should address a missed dose, detailing the conditions under which a dose should be taken or when it should be skipped.

Q: Is Flukonazol considered safe for long-term use?

A: Long-term use or repeated dosing has been studied and is associated with specific risks that require caution. These risks are why long-term use, when required, is associated with a need for close monitoring.

Q: Does taking Flukonazol cause yeast infections to become resistant to treatment?

A: Studies and official guidelines acknowledge that using Flukonazol, particularly for prevention (prophylaxis) or over long periods, is associated with the emergence of resistance. This means that fungal species may, over time, develop resistance to the 'azole' class of medicines.

Q: Can Flukonazol be used to prevent infections?

A: Flukonazol is officially approved for prophylaxis, or preventive use, in certain high-risk patient groups. This application is indicated for specific severely immunocompromised individuals, such as those undergoing a bone marrow transplantation.

Q: Does Flukonazol interact with herbal supplements?

A: Official patient information regarding drug interactions notes that specific caution is described regarding the combination of herbal remedies and supplements with Flukonazol. Regulatory patient information states that there is not enough data available to confirm the safety of concurrent use.

Q: Does Flukonazol affect cholesterol levels?

A: Official laboratory findings have documented that the use of Flukonazol can be associated with changes in blood lipids. These changes can include an increase in cholesterol and triglyceride levels.

Q: Can Flukonazol be taken by people with diabetes?

A: People with diabetes who are taking blood sugar-lowering medications, such as insulin or sulfonylureas, must be aware of potential drug interactions. Official information indicates that combining these with Flukonazol may enhance the effect of the blood sugar medicine. Close monitoring is generally described as part of the management of this interaction.

Q: Does Flukonazol cause changes in taste?

A: A change in the way food tastes, known clinically as dysgeusia, is noted as an occasional adverse effect listed in the official product information for Flukonazol.

Q: Are there any official warnings about driving or operating machinery while taking Flukonazol?

A: Official warnings state that caution should be exercised before driving or operating machinery, as occasional effects like dizziness or seizures have been reported with the use of Flukonazol.

Q: Does Flukonazol come with a Patient Information Leaflet?

A: Regulatory procedures require that Flukonazol be provided with a Patient Information Leaflet (PIL) or Medication Guide. This document provides full details on administration and safety.

Q: Is it common to feel tired after taking Flukonazol?

A: General weakness or unusual tiredness is not listed as a common side effect in official information. However, this symptom is noted as a possible sign associated with rare but serious adverse reactions, such as severe hepatic toxicity (liver damage) or reduced adrenal function.

How should Flukonazol be stored and disposed of?

How to Store and Dispose of Fluconazole

Storage and handling requirements for Fluconazole (Flukonazol) are defined by the specific dosage form to maintain product stability and safety. All forms must be kept out of the sight and reach of children.

Storage Requirements

Dosage Form	Required Storage Condition
Tablets & Dry Powder	Store below 30 C (86 F).
Reconstituted Suspension	Store between 5 C (41 F) and 30 C (86 F).

The reconstituted oral suspension and the injection solution must be protected from freezing. The medication should be stored in its tightly closed original container and away from excessive heat and moisture.

Stability and Disposal

The prepared oral suspension has a limited shelf-life and must be discarded after 14 days even if some medication remains. Expired or unused product should be disposed of safely according to local requirements, such as through a drug take-back program. Medicines should generally not be flushed down a toilet or sink.

Flukonazol